Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.
Clinical trial NCT06296212 · UNKNOWN
Trial details
- NCT number
- NCT06296212
- Sponsor
- Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-25
- Primary completion
- 2025-06-01
- Enrollment
- 178
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.